US FDA Willing And Ready To Approve Novel Cardiac Troponin Assays
Executive Summary
Rumors that FDA has raised the bar too high for clearing cardiac troponin assays to predict myocardial infarction "are not true," a device center reviewer said at an agency workshop. FDA is open to novel tests and wants industry to give it direction on clinically meaningful cut-off levels of troponin for assays. Also, FDA issued a safety alert on consumer overuse of Biotin (Vitamin B7) for aesthetic purposes, which can interfere with the results of the assays.
You may also be interested in...
Cardiac Troponin Assays Will Get US FDA Attention At November Workshop
Troponin assays are routine tools for diagnosing heart attacks, but there have been challenges on the regulatory front, as testing standards evolve and technology rapidly improves. The agency has called a public meeting for late November to discuss scientific and regulatory challenges for troponin assays and more efficient development strategies.
Trinity Pulls 510(k) For Troponin Point-Of-Care Test
Trinity Biotech said US FDA may be expecting its point-of-care troponin assay to match the performance of laboratory-based systems and, as a result, it is withdrawing it its pending 510(k) submission. The firm said FDA has expressed concerns that the company's system has not met the agency's sensitivity threshold and is unable to operate in a wide enough temperature range.
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.